Randomized, double-blind phase II trial of NY-ESO-1 ISCOMATRIX vaccine and ISCOMATRIX adjuvant alone in patients with resected stage IIc, III, or IV malignant melanoma.
Year: 2014
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Jonathan S. Cebon, Grant A. McArthur, Weisan Chen, Ian D. Davis, Martin Eric Gore, John F Thompson, Michael Millward, Michael P. N. Findlay, Rod Dunbar, Christian H.H Ottensmeier, Ralph Rudolph Venhaus, Paul D. Nathan, Angus George Dalgleish, Vincenzo Cerundolo, Eugene Maraskovsky, Wendie Hopkins, Jeremy Marsden, B Mark Smithers, Peter Hersey, T.R. Jeffry Evans
Institutions: Ludwig Cancer Research, Peter MacCallum Cancer Centre, Peter MacCallum Cancer Foundation, Eastern Health, Monash University, Royal Marsden NHS Foundation Trust, Royal Marsden Hospital, The University of Sydney, Royal Prince Alfred Hospital, Melanoma Institute Australia, Sir Charles Gairdner Hospital, University of Auckland, Cancer Trials New Zealand, University Hospital Southampton NHS Foundation Trust, Ludwig Cancer Research, Mount Vernon Hospital, Mount Vernon Cancer Centre, St George's, University of London, MRC Weatherall Institute of Molecular Medicine, CSL (Australia), University of Birmingham, Princess Alexandra Hospital, Beatson West of Scotland Cancer Centre, University of Glasgow
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2600479727